Instinct Bio Completes Business Combination with Relativity Acquisition Corp. and Makes Its Nasdaq Debut Under the Ticker “BIOT” on July 24, 2026

Instinct Bio has completed its SPAC merger with Relativity Acquisition Corp. and commenced trading on Nasdaq under the new ticker BIOT on July 24, 2026. The combined entity established a pro forma enterprise value of approximately $288 million, positioning itself as a dedicated pure-play platform focused on regenerative medicine and longevity therapeutics.

This represents a standard capital formation event rather than a fundamental market catalyst. SPAC mergers are routine liquidity events for private life sciences companies seeking public market access, with no disclosed product approvals, clinical trial data, or partnership announcements that would constitute material catalyst risk. The $288 million valuation sits modestly within biotech standards for early-to-mid stage platforms lacking commercial revenue.

As a newly public micro-cap health care entity, BIOT will exhibit limited correlation with broader equity markets given its nascent public status and concentrated risk profile. The regenerative medicine and longevity sector remains underpenetrated at the public market level, but this entrance carries execution risk typical of pre-commercial biotech ventures dependent on R&D success and capital availability.

Sector implication: Health Care sector exposure is elevated but directionally neutral—this is a supply-side event (new public float) rather than demand-side (institutional rotation). Longevity and regenerative medicine remain emerging thematic areas with high speculative retail interest but limited institutional conviction at this valuation tier.